Crystal structure, spectral characterization, in vitro, molecular docking and DFT studies of pyranopyrazole derivatives

Abstract

Two Pyranopyrazole derivatives, namely, methyl-11-(2-chlorophenyl)-16-methyl-8-[(4-methylbenzene)sulfonyl], -14-phenyl-12-oxa-8,14,15-triazatetracyclo[8.7.0.02,7.013,17] heptadeca-2(7), 3, 5, 13(17), 15-pentaene-10-carboxylate, C38H37N3S1O5 and butyl‑16-methyl-8-[(4-methylbenzene)sulfonyl]-11,14-diphenyl-12-oxa-8,14,15-triazatetracyclo[8.7.0.02,7.013,17] heptadeca-2(7),3,5, 13(17), 15-pentaene-10-carboxylate, C35 H30 Cl N3 O5 S with phenyl and chlorophenyl substitutions were synthesized successfully, and crystallized by the slow evaporation technique. The pyranopyrazole derivatives were characterized by spectroscopic techniques including UV–visible, FTIR, and mass spectroscopy, and their 3D-structural arrangements were also confirmed by single crystal XRD studies. Both compounds crystallize in the triclinic crystal system with the centrosymmetric space group P-1, which is identified by the X-ray single-crystal structure. These compounds were examined for in vitro and molecular docking studies with the enzymes 1hny, 1pgg, and 4 cox and thus correspond to diabetes and inflammation. The observed results showed better binding energy and inhibition constants for inflammation involving enzymes. The chemical reactivity and electronic arrangement of the compounds have been revealed by DFT studies.